Engineering Nme2cas9 And Spycas9 For Improved Gene Editing Activities

Patent Status

Patent Pending

Brief Description

UC Berkeley researchers have created variant CRISPR-Cas effector polypeptides (e.g., variant Cas9 proteins) with improved properties, such as improved editing efficiency and/or improved PAM sequence flexibility, as well as methods of modifying a target nucleic acid using a variant CRISPR-Cas effector polypeptide and methods of generating variant CRISPR-Cas effector polypeptides.

Suggested uses

• In vivo gene editing
• Therapeutic applications